159870-89-0 Usage
General Description
C6H2Cl2N2S is a chemical compound with the molecular formula C6H2Cl2N2S. It is a yellow crystalline compound that is commonly used in the production of dyes, pigments, and various organic compounds. It is also utilized as a pesticide and as a precursor for the synthesis of pharmaceuticals and agrochemicals. C6H2Cl2N2S is classified as a chlorinated sulfonamide, a group of chemicals that are known for their antimicrobial properties and are used in the production of antibacterial and antifungal agents. Additionally, C6H2Cl2N2S is an important intermediate in the synthesis of various industrial chemicals and can also be used in the manufacturing of rubber, textiles, and plastics.
Check Digit Verification of cas no
The CAS Registry Mumber 159870-89-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,9,8,7 and 0 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 159870-89:
(8*1)+(7*5)+(6*9)+(5*8)+(4*7)+(3*0)+(2*8)+(1*9)=190
190 % 10 = 0
So 159870-89-0 is a valid CAS Registry Number.
159870-89-0Relevant articles and documents
BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY
-
Page/Page column 93; 94, (2017/09/27)
The present invention relates to the compounds of formula (I) that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (a-synuclein, A- synuciein, aSynuciein, A-syn, a-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.
